Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML)

European Journal of Haematology

Volumn 83, Issue 6, 2009, Pages 611-612

  Hackanson, Björn ^a   Rückert, Anja ^a   Lübbert, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADALIMUMAB; ALPHA INTERFERON; CYTARABINE; HEMOGLOBIN; HYDROXYUREA; IMATINIB; NILOTINIB;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; BLAST CELL; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CYTOGENETICS; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; KARYOTYPE 46,XY; LETTER; LEUKOCYTE COUNT; LEUKOCYTOSIS; LOW DRUG DOSE; MALE; METAPHASE; MONOSOMY 7; MULTIPLE CYCLE TREATMENT; MYCOSIS; PANCYTOPENIA; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REMISSION; TREATMENT RESPONSE;

AGED; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 7; CYTARABINE; DISEASE PROGRESSION; FATAL OUTCOME; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; LEUKOCYTOSIS; MALE; MONOSOMY; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SELECTION, GENETIC;

EID: 70449463345     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01335.x     Document Type: Letter

References (8)

1. Jabbour E, Kantarjian H, Abruzzo LV, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007 110 : 2991 2995.
2. Bumm T, Müller C, Al-Ali HK, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib cut restoration of polyclonal hematopoiesis in the majority. Blood 2003 101 : 1941 1949.
3. Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004 18 : 1340 1346.
4. Lübbert M, Rüter B, Claus R, et al. Continued low-dose decitabine (DAC) is an active first-line treatment in all cytogenetic subgroups of older AML patients: results of the FR00331 multicenter phase II study [abstract]. Blood 2007 110 : 300.
5. Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007 21 : 1937 1944.
6. Rüter B, Wijermans P, Claus R, Kunzmann R, Lübbert M. Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood 2007 110 : 1080 1082.
7. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006 108 : 2811 2813.
8. Perel JM, McCarthy C, Walker O, Irving I, Williams B, Kennedy GA. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica 2005 90 (Suppl. ECR25.